Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ardelyx, Inc. - Common Stock (NQ:ARDX)

3.685 +0.055 (+1.52%)
Streaming Delayed Price Updated: 3:47 PM EDT, Jun 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ardelyx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Ardelyx to Participate at the 2024 Cantor Global Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ardelyx and Symbotic and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Shareholder Rights Law Firm Robbins LLP Urges ARDX Stockholders with Large Losses to Contact the Firm for Information About the Ardelyx, Inc. Lawsuit
From Robbins LLP
Via Business Wire
ARDX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ardelyx, Inc. Investors Can Join the Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DXC, Ardelyx, Symbotic, and Five Below and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx
From Faruqi & Faruqi LLP
Via GlobeNewswire
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ARDX
From The Rosen Law Firm PA
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DXC, Ardelyx, Symbotic, and Five Below and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ARDX Class Action Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Ardelyx, Inc. Class Action
From Robbins LLP
Via GlobeNewswire
ARDX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ardelyx, Inc. Investors Can Join the Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
ARDELYX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Ardelyx, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Ardelyx, Inc. Investor Notice: Robbins LLP Reminds Shareholders of the Pending ARDX Class Action
From Robbins LLP
Via Business Wire
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx
From Faruqi & Faruqi, LLP
Via Business Wire
Rosen Law Firm Urges Ardelyx, Inc. (NASDAQ: ARDX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
Stockholder Alert: Robbins LLP Informs Ardelyx, Inc. Stockholders of the Class Action Against ARDX
From Robbins LLP
Via GlobeNewswire
Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH® (tenapanor) Clinical Trials in Current Medical Research and Opinion
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024
Conference call scheduled for 4:30 p.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines
From Ardelyx, Inc.
Via GlobeNewswire
To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
From Ardelyx, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.